Table 3.
Estimated effects of dulaglutide on the first composite outcome
| Composite event | Dulaglutide group | Placebo group | People spareda | Cox model | |
|---|---|---|---|---|---|
| N (N/1000py) | N (N/1000py) | N (N/1000py) | HR (95% CI) | p | |
| MACE or non-CV death | 789 (31.2) | 879 (35.3) | 90 (4.1) | 0.88 (0.80, 0.97) | 0.011 |
| MACE, UA, or non-CV death | 859 (34.3) | 933 (37.8) | 74 (3.5) | 0.91 (0.83, 0.99) | 0.041 |
| MACE, HF or non-CV death | 880 (35.3) | 983 (40.1) | 103 (4.8) | 0.88 (0.80, 0.96) | 0.0054 |
| MACE, Revasc, or non-CV death | 1002 (40.8) | 1090 (44.9) | 88 (4.1) | 0.91 (0.83, 0.99) | 0.028 |
| MACE, UA, HF, Revasc, or non-CV death | 1097 (45.3) | 1189 (49.8) | 92 (4.5) | 0.91 (0.84, 0.99) | 0.024 |
aDifference in numbers (and rate) of people experiencing a first composite event in the dulaglutide group versus the placebo group; CV, cardiovascular; py, person-year; MACE, major adverse cardiovascular events; UA, unstable angina; HF, heart failure; Revasc, revascularization